万维书刊网微信二维码

扫微信,关注编辑QQ!

您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生1>>肿瘤学

ONCOLOGY《肿瘤学》 (官网投稿)

简介
  • 期刊简称ONCOLOGY-BASEL
  • 参考译名《肿瘤学》
  • 核心类别 SCI期刊(2019), SCIE期刊(2019), 外文期刊,
  • IF影响因子2.642 (2019)
  • 自引率1.90%
  • 主要研究方向医学-ONCOLOGY 肿瘤学

主要研究方向:

等待设置主要研究方向
医学-ONCOLOGY 肿瘤学

ONCOLOGY《肿瘤学》(月刊). This journal works to accelerate the translation of experimental results into the clinic and back again into th...[显示全部]
征稿信息

万维提示:

1、投稿方式:在线投稿。

2、期刊网址:

https://www.karger.com/Journal/Home/223857

3、投稿网址:

https://www.manuscriptmanager.net/OCL?product_id=223857

4、官网邮箱:ocl@karger.com

5、官网电话:+41 61 306 13 59

6、期刊刊期:月刊,一年出版十二期。

2021520日星期四

                             

 

投稿须知【官网信息】

 

Author Guidelines

About the Journal

Aims and Scope

This journal works to accelerate the translation of experimental results into the clinic and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically relevant knowledge of cancer and improve the outcome of prevention, diagnosis, and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted), and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a section which focuses on rapid peer review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of ensuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.

Journal Sections

Clinical Studies and Clinical Translational Research Articles

These research articles cover topics relevant to clinical and translational studies in all oncological fields. Note that manuscripts presenting laboratory-based research efforts must address a clinically relevant issue (Translational Research).

Clinical Trial Notes

These papers are brief reports of clinical trials, with a particular focus on phase 1, phase 1/2, and phase 2 studies. Priority in this section will not be for studies with a ‘positive result’, but rather for well-conceived and conducted clinical research efforts. The maximum length of manuscripts submitted in this category will be 1,500 words, with a maximum of 2 tables and 1 figure. The paper should be divided into four sections: Introduction, Methods, Results, Discussion. Note that all manuscripts submitted in this category will undergo rapid review for acceptance or rejection.

Reducing the Worldwide Burden of Cancer

These are country reports describing a variety of regional, national or international efforts that focus on the unique aspects of the epidemiology of cancer, and the delivery of educational messages, preventive services, and oncology-related care within the developing world. Papers submitted for this section benefit from a higher quota of free pages.

Article Types

Research Article

Research Articles report on primary research. They must describe significant and original observations. Consideration for publication is based on the article’s originality, novelty, and scientific soundness, and the appropriateness of its analysis.

Research Articles are reports of original work. Authors are asked to follow the EQUATOR Network for Research Articles.

Prior approval from an Institutional Review Board (IRB) or an Ethics Review Committee is required for all investigations involving human subjects.

A downloadable template is available below.

Documents

Research Article (DOCX, 28.97 KB)

Research articles should contain a 300-word abstract.

Review Article

Review Articles are considered reviews of research or summary articles. They are state-of-the-art papers covering a current topic by experts in the field. They should give evidence on and provide answers to a well-defined aspect or question in a particular area. Review Articles must include a critical discussion of the reported data and give a clear conclusion with potential impacts on the standard of care.

A downloadable template is available below.

Documents

Review Article (DOCX, 23.66 KB)

Review articles should contain 5,000 words for text and tables (a table = 250 words, per page), with a maximum of 5 tables and 50 references.

Brief Report

Brief Reports are short and/or rapid announcements of research results. They must contain data derived from cutting-edge research and be of potential interest to a large proportion of the readership. They are independent, concise reports representing a significant contribution to the field. Such communications should represent complete, original studies and should be arranged in the same way as full-length manuscripts with subheadings.

A downloadable template is available below.

Documents

Brief Report (DOCX, 27.12 KB)

Brief reports should contain 1'000 words in total.

Editorial

Editorials provide a viewpoint on specific articles or on general subjects directly relevant to the journal. Editorials are written by an editor or other member of the journal.

Editorials should not exceed 500 words

A downloadable template is available below.

Documents

Editorial (DOCX, 24.95 KB)

Editorials should contain 1'500 words in total, up to 10 references and no abstract.

Letter

Letters may explore subjects related to matters discussed in the journal, providing the author’s perspective on a subject. Letters may discuss a recently published article and may lend support or constructively critique the article in line with the author’s experience. The editors reserve the right to share such letters to the authors of the article concerned prior to publication in order to permit response, ideally in the same issue of the journal. Letters should not include original data.

Letters should not exceed 2000 words and have a maximum 15 references & 1 figure/table

A downloadable template is available below.

Documents

Letter (DOCX, 24.24 KB)

Letters should contain 500 words in total and no abstract.

Contact Information

Should you have any problems with your submission, please contact the editorial office:

Patricia Bachmann

Editorial Office 'Oncology'

S. Karger AG

P.O. Box

CH–4009 Basel (Switzerland)

Tel. +41 61 306 1359

Fax +41 61 306 1434

ocl@karger.com

Editorial and Journal Policies

General Conditions

Only papers written in English are considered. The articles should be comprehensible to a reader who is fluent in English and should be edited prior to submission to ensure that standard English grammar and usage are observed. Use of a professional language editing service prior to submission can help avoid delays with the review process.

All manuscripts are subject to editorial review.

The presentation of manuscripts should follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals from the International Committee of Medical Journal Editors (ICMJE).

Karger journals aim to adhere to the COPE Code of Conduct and Best Practice Guidelines.

By submitting an article for publication, the authors agree to the transfer of the copyright to the publisher upon acceptance. Accepted papers become the permanent property of the Journal and may not be reproduced by any means, in whole or in part, without the written consent of the publisher.

The Submission Statement with original (hand-written) signatures is to be provided upon submitting the paper. If it is not possible to collect all signatures on a single document, individual copies should be provided for each author.

Karger recommends the use of original images and materials whenever possible. If a submitted manuscript contains third-party copyright material(s), it is the authors’ sole responsibility to obtain permission from the relevant copyright holder for reusing the material(s), including any associated licensing fee. The copyright and usage information needs to be checked carefully to avoid copyright infringement.

Most publishers offer a quick and easy way to clear permissions for their content via the built-in website application RightsLink or via https://www.copyright.com/get-permissions/. Another widely used licensing tool is PLSClear. Please check the publishers websites for the available options and user instructions.

Statements

All submitted manuscripts must contain a Statement of Ethics, a Conflict of Interest Statement, an Author Contributions Statement and a Data Availability Statement after the main body of the text, but before the reference list.

Statement of Ethics

Published research must comply with internationally-accepted standards for research practice and reporting. Manuscripts may be rejected if the editors believe that the research has not been carried out within an appropriate ethical framework, and concerns raised after publication may lead to a correction, retraction, or expression of concern in line with COPE guidelines.

Studies involving human subjects (including research on identifiable human material and data) must have been performed with the approval of an appropriate ethics committee and with appropriate participants’ informed consent in compliance with the Helsinki Declaration.

In the manuscript, authors should specify the name of the ethics committee or other relevant authority who approved the study protocol and provide the reference number where appropriate. If ethics approval was not required, or if the study has been granted an exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee who made that decision).

For all research involving human subjects, written informed consent to participate in the study should be obtained from participants (or their parent/legal guardian  where appropriate  ) and a statement detailing this should appear in the manuscript. For studies involving vulnerable participants or participants at risk of potential coercion, detailed information regarding the steps taken to ensure informed consent must be provided. If consent was not obtained, please specify why and whether this was approved by the ethics committee.

In line with the ICMJE recommendations on the protection of research participants, authors must avoid providing identifying information unless strictly necessary for the submission and participants’ identifiable attributes must be anonymized in the manuscript and its supplementary files, if any. If identifying information is necessary, authors must confirm that the individual has provided written consent for the use of that information in a publication.

Research involving human embryonic stem cells, embryonic germ cells or induced pluripotent stem cells should comply with the ISSCR 'Guidelines for the Conduct of Human Embryonic Stem Cell Research' or an equivalent set of guidelines or applicable regulations.

Case Reports: Manuscripts reporting a case report must include a statement detailing that written informed consent for publication was obtained and from whom (e.g. “Written informed consent was obtained from the patient for publication of this case report and any accompanying images.”). If the patient has died, consent for publication must be obtained from their next of kin. If the patient described in the case report is a minor or vulnerable, then consent for publication must be obtained from the parent/legal guardian. The completed consent form must be made available to the Editor if requested, and will be treated confidentially.

Clinical Trials:  In accordance with the ICMJE recommendations, all clinical trials should be registered in a publicly available registry approved by the WHO or ICMJE (see the list here) and the clinical trial number must be clearly stated in the manuscript. Manuscripts reporting clinical trials must adhere to the relevant reporting guidelines for their study design, such as CONSORT for randomized controlled trials, TREND for non-randomized trials, or other relevant reporting guidelines as detailed on the Equator network website.

Karger follows the WHO definition of clinical trials "A clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes [...] Interventions include but are not restricted to drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioural treatments, process-of-care changes, preventive care, etc. This definition includes Phase I to Phase IV trials.”

Studies involving animals: Experimental research on vertebrates or any regulated invertebrates must have been approved by the authors' Institutional Animal Care and Use Committee (IACUC) or equivalent ethics committee and must follow internationally recognized guidelines such as the ARRIVE guidelines. In the manuscript, authors should specify the name of the ethics committee or other relevant authority who approved the study protocol and provide the reference number where appropriate.

If ethics approval was not required, or if the study has been granted an exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee who made that decision). Additional information is expected for studies reporting death of a regulated animal as a likely outcome or planned endpoint. Other types of studies including field studies and non-experimental research on animals must comply with local or international guidelines, and where appropriate must have been approved by an appropriate ethics committee.

Conflict of Interest Statement

Karger endorses the ICMJE recommendations on the ‘Disclosure of Financial and Non-Financial Relationships and Activities, and Conflicts of Interest’. Authors are required to disclose any relationship that could reasonably be perceived by a reader as a potential conflict of interest at the time of submission. All forms of support and financial involvement (e.g. employment, consultancies, honoraria, stock ownership and options, expert testimony, grants or patents received or pending, royalties) which took place in the previous three years should be listed, regardless of their potential relevance to the paper. Also the nonfinancial relationships (personal, political, or professional) that may potentially influence the writing of the manuscript should be declared. The role of the funder in study design; collection, analysis, and interpretation of data; writing of the report; any restrictions regarding the submission of the report for publication should be declared. If the funder had no role in any of the above, this should be clearly stated in the manuscript’s funding section.

Author Contributions Statement

In the Author Contributions section, a short statement detailing the contributions of each person named as an author should be included. Contributors to the paper who do not fulfill the ICMJE Criteria for Authorship should be credited in the Acknowledgement section. If an author is removed from or added to the listed authors after submission, an explanation and a signed statement of agreement confirming the requested change are required from all the initially listed authors and from the author to be removed or added.

Data Availability Statement

The journal’s data sharing policy strongly encourages authors to make all datasets on which the conclusions of the paper rely available to editors, reviewers and readers without unnecessary restriction wherever possible. Authors are required to provide a Data Availability Statement in their article that details whether data are available and where they can be found. In cases where research data are not publicly available on legal or ethical grounds, this should be clearly stated in the Data Availability Statement along with any conditions for accessing the data. The decision to publish will not be affected by whether or not authors share their research data.

Examples of Data Availability statements:

·                    The data that support the findings of this study are openly available in [repository name e.g “figshare”] at http://doi.org/[doi], reference number [reference number]

·                     Publicly available datasets were used in this study. These can be found in [repository name e.g “figshare”] at http://doi.org/[doi], reference number [reference number]

·                    All data generated or analyzed during this study are included in this article [and/or] its supplementary material files. Further enquiries can be directed to the corresponding author.

·                    The data that support the findings of this study are not publicly available due to [REASON WHY DATA ARE NOT PUBLIC e.g. their containing information that could compromise the privacy of research participants] but are available from [e.g. the corresponding author [author initials] OR Data sharing committee [PROVIDE CONTACT DETAILS including email address] upon reasonable request]

·                    The data in this study was obtained from [third party source] where [RESTRICTIONS/LICENCE] may apply. Such dataset may be requested from [source contact information].

Please note if authors are submitting to a journal with a double blind peer review policy, the data availability statement should be anonymized where appropriate.

Definition of research data: This policy applies to the research data that would be required to verify the results of research reported in articles published in the journal. Research data include data produced by the authors (“primary data”) and data from other sources that are analysed by authors in their study (“secondary data”). Research data includes any recorded factual material that are used to produce the results in digital and non-digital form. This includes, but is not limited to, tabular data, code, images, audio, documents, video, maps, raw and/or processed data.

For images, Karger requests that individual/unique features within an image are not modified, and image-processing methods do not alter the original image information ( the use of software and/or enhancement technique must be disclosed in the methods section). Any concerns raised over inappropriate image modification will be investigated in accordance with COPE guidelines.

Policy exceptions: This policy does not require public sharing of quantitative or qualitative data that could identify a research participant unless participants have consented to data release. The policy also does not require public sharing of other sensitive data, such as the locations of endangered species. Alternatives to public sharing of sensitive or personal data include:

Depositing research data in controlled access repositories

Anonymizing or deidentifying data before public sharing

Only sharing metadata about the research data

Stating the procedures for accessing your research data in the article and managing data access requests from other researchers

Embargoes: Embargoes on data sharing are permitted but should be clearly stated in the data availability statement, including the reason for embargo, date of the end of the embargo period and how and where the data can be accessed following the end of the embargo period. Please note that all datasets on which the conclusions of the paper rely must be made available to editors and reviewers if requested to facilitate the review process.

Data repositories: The preferred mechanism for sharing research data is via public data repositories. We encourage authors to select a data repository that issues a persistent identifier, preferably a Digital Object Identifier (DOI), and has established a robust preservation plan to ensure the data is preserved in perpetuity. Additionally, we highly encourage researchers to consider the FAIR Data Principles when depositing data. Authors are encouraged to deposit their research data in a repository that has been widely adopted within their research community, suitable repositories per each area and data type can be searched using the FAIRsharing database tool (https://fairsharing.org/databases/) or via https://repositoryfinder.datacite.org.

……

更多详情:

https://www.karger.com/Journal/Guidelines/223857


投稿问答最小化  关闭